Long Term Percutaneous Coronary Interventions Outcomes in Cancer Survivors

Objectives: To examine the prevalence and long term outcome of cancer-survivors among all-comers PCI patients cohort.

Background: Cancer patients are mostly excluded from PCI clinical trials and oncologic history is lacking from most PCI registries. Thus, little is known about the clinical outcomes following PCI among cancer survivors.

Methods: Data upon 12,785 consecutive patients who underwent PCI at our center between Apr-2004 and Octob-2014 was collected. Patients oncologic background was retrieved from the medical centers` central laboratory database and cancer-survivors were compared with pair matched cancer-naïve patients.

Results: Cancer-survivors constituted 7.8% (1,005) of the patients. Mean cancer diagnosis-to-PCI time was 3.6 (±3.4) years and mean post-PCI follow-up time was 5.9 years. Post matching baseline characteristics were similar between the groups. Cancer-survivors were more likely to arrive at the catheterization laboratory due to ACS, to be treated with BMS and less so with DES. Cancer-survivors to cancer-naive patients Hazard-Ratio (HR) and 95% confidence interval (CI) were 1.46 (1.24-1.72), p

Conclusions: Cancer survivors constitute a substantial portion of the PCI population (1 in every 13 patients) and are subjected for approximately 40% increased risk for cardiovascular morbidity and death. Cardiac disease etiology is a leading cause of in-hospital mortality among these patients.